79 related articles for article (PubMed ID: 10220486)
1. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
Kwei GY; Alvaro RF; Chen Q; Jenkins HJ; Hop CE; Keohane CA; Ly VT; Strauss JR; Wang RW; Wang Z; Pippert TR; Umbenhauer DR
Drug Metab Dispos; 1999 May; 27(5):581-7. PubMed ID: 10220486
[TBL] [Abstract][Full Text] [Related]
2. Loperamide modifies the tissue disposition kinetics of ivermectin in rats.
Lifschitz AL; Virkel GL; Sallovitz JM; Pis A; Imperiale FA; Lanusse CE
J Pharm Pharmacol; 2004 Jan; 56(1):61-7. PubMed ID: 14980002
[TBL] [Abstract][Full Text] [Related]
3. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
Smit JW; Schinkel AH; Weert B; Meijer DK
Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
[TBL] [Abstract][Full Text] [Related]
4. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
5. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition.
Ballent M; Lifschitz A; Virkel G; Sallovitz J; Lanusse C
J Vet Pharmacol Ther; 2007 Jun; 30(3):242-8. PubMed ID: 17472656
[TBL] [Abstract][Full Text] [Related]
6. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
[TBL] [Abstract][Full Text] [Related]
7. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Schinkel AH; Wagenaar E; van Deemter L; Mol CA; Borst P
J Clin Invest; 1995 Oct; 96(4):1698-705. PubMed ID: 7560060
[TBL] [Abstract][Full Text] [Related]
8. Sex-related differences in the gastrointestinal disposition of ivermectin in the rat: P-glycoprotein involvement and itraconazole modulation.
Lifschitz A; Ballent M; Virkel G; Sallovitz J; Lanusse C
J Pharm Pharmacol; 2006 Aug; 58(8):1055-62. PubMed ID: 16872551
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments.
Ballent M; Lifschitz A; Virkel G; Sallovitz J; Lanusse C
Drug Metab Dispos; 2006 Mar; 34(3):457-63. PubMed ID: 16381664
[TBL] [Abstract][Full Text] [Related]
10. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
11. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.
Chen C; Pollack GM
J Pharmacol Exp Ther; 1998 Nov; 287(2):545-52. PubMed ID: 9808679
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
Schuetz EG; Umbenhauer DR; Yasuda K; Brimer C; Nguyen L; Relling MV; Schuetz JD; Schinkel AH
Mol Pharmacol; 2000 Jan; 57(1):188-97. PubMed ID: 10617694
[TBL] [Abstract][Full Text] [Related]
13. Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin.
Janko C; Geyer J
J Vet Pharmacol Ther; 2013 Jun; 36(3):275-84. PubMed ID: 22834856
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.
Smit JW; Schinkel AH; Müller M; Weert B; Meijer DK
Hepatology; 1998 Apr; 27(4):1056-63. PubMed ID: 9537446
[TBL] [Abstract][Full Text] [Related]
15. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
16. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition.
Ballent M; Lifschitz A; Virkel G; Mate L; Lanusse C
J Vet Pharmacol Ther; 2010 Jun; 33(3):252-9. PubMed ID: 20557442
[TBL] [Abstract][Full Text] [Related]
19. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
